Scancell Holdings plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more
Scancell Holdings plc (SCNLF) - Net Assets
Latest net assets as of October 2025: $-8.38 Million USD
Based on the latest financial reports, Scancell Holdings plc (SCNLF) has net assets worth $-8.38 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.39 Million) and total liabilities ($23.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.38 Million |
| % of Total Assets | -54.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | -150.14% |
| 10-Year Change | -138.38% |
| Growth Volatility | 115.65 |
Scancell Holdings plc - Net Assets Trend (2007–2025)
This chart illustrates how Scancell Holdings plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scancell Holdings plc (2007–2025)
The table below shows the annual net assets of Scancell Holdings plc from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $-3.83 Million | -9.42% |
| 2024-04-30 | $-3.50 Million | +43.77% |
| 2023-04-30 | $-6.23 Million | -131.99% |
| 2022-04-30 | $19.48 Million | +154.77% |
| 2021-04-30 | $7.65 Million | -18.09% |
| 2020-04-30 | $9.34 Million | 0.00% |
| 2019-04-30 | $9.34 Million | -33.03% |
| 2018-04-30 | $13.94 Million | +114.50% |
| 2017-04-30 | $6.50 Million | -34.96% |
| 2016-04-30 | $9.99 Million | +47.95% |
| 2015-04-30 | $6.75 Million | -25.59% |
| 2014-04-30 | $9.08 Million | +78.26% |
| 2013-04-30 | $5.09 Million | -26.96% |
| 2012-04-30 | $6.97 Million | +50.37% |
| 2011-04-30 | $4.64 Million | -23.35% |
| 2010-04-30 | $6.05 Million | +15.11% |
| 2009-04-30 | $5.25 Million | +401.72% |
| 2008-04-30 | $1.05 Million | -26.85% |
| 2007-04-30 | $1.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scancell Holdings plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8815114200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.04 Million | % |
| Other Comprehensive Income | $4.14 Million | % |
| Other Components | $82.40 Million | % |
| Total Equity | $-3.83 Million | 100.00% |
Scancell Holdings plc Competitors by Market Cap
The table below lists competitors of Scancell Holdings plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Merafe Resources Limited
F:RZT
|
$73.43 Million |
|
1SPATIAL PLC LS -10
F:G7Z1
|
$73.44 Million |
|
A.F.P. Provida
SN:PROVIDA
|
$73.44 Million |
|
Stemmer Imaging AG
XETRA:S9I
|
$73.45 Million |
|
SWANDEF
NSE:SWANDEF
|
$73.39 Million |
|
Renascor Resources Limited
PINK:RSNUF
|
$73.35 Million |
|
Chien Shing Harbour Service Co Ltd
TW:8367
|
$73.33 Million |
|
Metalfrio Solutions S.A
SA:FRIO3
|
$73.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scancell Holdings plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,505,000 to -3,835,000, a change of -330,000.
- Net loss of 12,272,000 reduced equity.
- New share issuances of 11,282,000 increased equity.
- Other comprehensive income increased equity by 1,357,999.
- Other factors decreased equity by 697,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.27 Million | -320.0% |
| Share Issuances | $11.28 Million | +294.19% |
| Other Comprehensive Income | $1.36 Million | +35.41% |
| Other Changes | $-698.00K | -18.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Scancell Holdings plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-04-30 | $0.09 | $0.13 | x |
| 2008-04-30 | $0.05 | $0.13 | x |
| 2009-04-30 | $0.03 | $0.13 | x |
| 2010-04-30 | $0.05 | $0.13 | x |
| 2011-04-30 | $0.03 | $0.13 | x |
| 2012-04-30 | $0.03 | $0.13 | x |
| 2013-04-30 | $0.02 | $0.13 | x |
| 2014-04-30 | $0.04 | $0.13 | x |
| 2015-04-30 | $0.03 | $0.13 | x |
| 2016-04-30 | $0.04 | $0.13 | x |
| 2017-04-30 | $0.02 | $0.13 | x |
| 2018-04-30 | $0.04 | $0.13 | x |
| 2019-04-30 | $0.02 | $0.13 | x |
| 2020-04-30 | $0.02 | $0.13 | x |
| 2021-04-30 | $0.03 | $0.13 | x |
| 2022-04-30 | $0.02 | $0.13 | x |
| 2023-04-30 | $-0.01 | $0.13 | x |
| 2024-04-30 | $0.00 | $0.13 | x |
| 2025-04-30 | $0.00 | $0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scancell Holdings plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -260.50%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-24.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 62.20% | 40.92% | 1.33x | 1.14x | $747.38K |
| 2008 | -38.70% | -175457.58% | 0.00x | 1.08x | $-510.03K |
| 2009 | -14.96% | 0.00% | 0.00x | 1.03x | $-1.31 Million |
| 2010 | -28.72% | 0.00% | 0.00x | 1.07x | $-2.34 Million |
| 2011 | -35.57% | 0.00% | 0.00x | 1.03x | $-2.11 Million |
| 2012 | 7.99% | 0.00% | 0.00x | 1.04x | $-140.08K |
| 2013 | -37.35% | 0.00% | 0.00x | 1.06x | $-2.41 Million |
| 2014 | -24.49% | 0.00% | 0.00x | 1.06x | $-3.13 Million |
| 2015 | -35.75% | 0.00% | 0.00x | 1.09x | $-3.09 Million |
| 2016 | -25.85% | 0.00% | 0.00x | 1.06x | $-3.58 Million |
| 2017 | -54.54% | 0.00% | 0.00x | 1.08x | $-4.19 Million |
| 2018 | -30.09% | 0.00% | 0.00x | 1.05x | $-5.59 Million |
| 2019 | -60.27% | 0.00% | 0.00x | 1.13x | $-6.56 Million |
| 2020 | -58.97% | 0.00% | 0.00x | 1.13x | $-6.44 Million |
| 2021 | -79.43% | 0.00% | 0.00x | 0.45x | $-17.43 Million |
| 2022 | -11.40% | 0.00% | 0.00x | 2.71x | $-3.88 Million |
| 2023 | 0.00% | -226.45% | 0.17x | 0.00x | $-10.97 Million |
| 2024 | 0.00% | -226.45% | 0.22x | 0.00x | $-11.59 Million |
| 2025 | 0.00% | -260.50% | 0.20x | 0.00x | $-11.89 Million |
Industry Comparison
This section compares Scancell Holdings plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scancell Holdings plc (SCNLF) | $-8.38 Million | 62.20% | N/A | $73.42 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |